Abstract 101P
Background
Deep molecular analysis with high throughput technology has improved the outcomes of advanced cancer patients. The molecular tumor board has a fundamental role in guiding treatment offering the evaluation of those molecular variants beside the ESCAT 1 level of evidence.
Methods
2010 patients diagnosed with solid tumors were prospectively analyzed in our institution with an extensive NGS panel. Patients were molecularly selected to receive a molecular-matched treatment according to international guidelines or to be enrolled in early phase trials, based on the evaluation of a single institution multidisciplinary molecular tumor board.
Results
1726 of 2010 (85.9%) patients presented any genomic or transcriptomic alterations. Of those, 1086 (62.9%) presented with advanced disease. 128 patients (11.8%) received standard targeted agents. 161 (14.8%) patients presented with druggable mutations beyond ESCAT 1 level such as BRAFnoV600, FGFR, NRAS, PIK3CA, ERBB2 and DNA repair genes, and BRAF fusions. Finally, 67 (6.1%) of those patients entered an early-phase clinical trial to receive a novel molecular-matched approach.
Conclusions
We demonstrate the pivotal role of the institutional molecular tumor board in evaluating the results of an extensive NGS panel. This process optimizes the selection of experimental novel molecular-matched therapies.
Editorial acknowledgement
Clinical trial identification
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
35P - Whole exome sequencing reveals high frequency of Notch pathway mutations in Indian breast cancer cases
Presenter: Harsh Goel
Session: Cocktail & Poster Display session
Resources:
Abstract
36P - Abacavir potentiates the efficacy of doxorubicin in breast cancer cells via KDM5B Inhibition
Presenter: Anmi Jose
Session: Cocktail & Poster Display session
Resources:
Abstract
37P - Identification of immune profile in advanced cutaneous squamous cell carcinoma predicting immunotherapy response
Presenter: Alfonso Esposito
Session: Cocktail & Poster Display session
Resources:
Abstract
39P - MicroRNA as a promising molecular biomarker for liquid biopsy in breast cancer
Presenter: Giorgia Vesca
Session: Cocktail & Poster Display session
Resources:
Abstract
40P - Patient-based models to study infiltration heterogeneity in gliomas
Presenter: Ivana Manini
Session: Cocktail & Poster Display session
Resources:
Abstract
42P - HER2 aberration as a potential predictive biomarker for extrapulmonary small cell neuroendocrine carcinoma
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
43P - Assessment of methylation-specific genetic markers for reliable colorectal cancer detection and their potential in liquid biopsy applications
Presenter: Jiri Dvorak
Session: Cocktail & Poster Display session
Resources:
Abstract
44P - Calculated numerical karyotype with ultra low-coverage whole genome sequencing undercovers recurrent chromosomal aberrations in resectable colorectal cancer
Presenter: Thomas Samer Tarawneh
Session: Cocktail & Poster Display session
Resources:
Abstract
46P - Promising epi(genetic) biomarkers for ovarian tumor prognosis
Presenter: Ieva Vaicekauskaitė
Session: Cocktail & Poster Display session
Resources:
Abstract
47P - Integration of miRNA profiles and p53 mutations as biomarkers for predicting sensitivity and resistance to FGFR inhibitor CPL110 in cancer therapy
Presenter: Monika Skupinska
Session: Cocktail & Poster Display session
Resources:
Abstract